The agency has been brought in to develop a public affairs campaign for the charity, which funds grants into researching all types of arthritis and related conditions.
PLMR account director Chris Calland told PRWeek: ‘We’ll be rolling out a public affairs campaign this year, which will be Westminster-focused. We are looking to get arthritis a profile there that it hasn’t had to date.’
The agency win follows the appointment of Tracey Loftis to Arthritis Research UK as head of policy and public affairs, who joined last year from Cancer Research UK.
The agency has been brought on board for an initial six-month period.
The news comes after it has been revealed that arthritis patients could be given a £1 a day drug to delay progression of the disease and reduce the need for hip and knee replacements.
The drug, Strontium Ranelate, marketed as Protelos, is already used for people with osteoporosis because it prevents the bone dissolving and stimulates new growth.